Clinical Trials Information System (CTIS): Walk-in clinic - September 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 September 2024, 16:00 (CEST) to 18 September 2024, 17:00 (CEST)

Agenda - Ad-hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), 1 July 2024

Human medicines European public assessment report (EPAR): Cinacalcet Accordpharma, cinacalcet, Date of authorisation: 03/04/2020, Revision: 4, Status: Authorised

Questions and answers to stakeholders on the implications of Regulation (EU) 2023/1182 for centrally authorised medicinal products for human use

Orphan designation: Brentuximab vedotin Treatment of cutaneous T-cell lymphoma, 11/01/2012 Withdrawn

Orphan designation: monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin) Treatment of Hodgkin's lymphoma, 15/01/2009 Withdrawn

Orphan designation: monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E Treatment of peripheral T-cell lymphoma, 21/08/2019 Withdrawn

Annex XV - List of topiramate containing medicinal products in the European Union

Annex XV - List of topiramate containing medicinal products in the European Union

List of medicinal products under additional monitoring